New Data Recommend Continuous Monitoring of Lymphedema for Breast Cancer
In case you missed last month’s publication in Annals of Surgical Oncology, Cancer Network has highlighted key findings from the PREVENT study. The study emphasizes the crucial need for continuous lymphedema monitoring for at least three years after breast cancer therapy.
Early Intervention Matters: Prospective Surveillance in Lymphedema Management
Additional Data Published in “Annals of Surgical Oncology” Recommends Extended Monitoring of Lymphedema for Breast Cancer Patients
Comprehensive strategies in breast cancer-related lymphedema prevention: insights from a multifaceted program
Nurse Navigators Aid in Timely and Comprehensive Lymphedema Care
Timing of Breast Cancer Related Lymphedema Development Over 3 Years: Observations from a Large, Prospective Randomized Screening Trial Comparing Bioimpedance Spectroscopy (BIS) Versus Tape Measure
HealthCentral: Why Do Doctors Know So Little About Lymphedema?
Kevin MD: Navigating the challenges of breast cancer-related lymphedema
ImpediMed Appoints Google Financial Executive Fiona Bones to Board of Directors
Healio: 5 questions with oncology nurse, co-founder of Lymphedema Prevention Program
Infection Control Today: Comprehensive Guide to Lymphedema: Causes, Prevention, and Management Strategies
